Prolymphocytic leukaemia

Nouv Rev Fr Hematol (1978). 1982;24(6):343-7.

Abstract

A review of the main features of prolymphocytic leukaemia, based on 80 cases studied by the author since 1974, is presented. Prolymphocytes have a B-cell membrane phenotype with strong expression of surface Ig in 81% of cases (B-PLL) whilst the rest have T-cell markers (T-PLL). Both forms of the disease have distinct laboratory and clinical findings. T-PLL has a more aggressive course with a median survival of 7 months (24 months in B-PLL). Ultrastructural analysis demonstrates larger lysosomal granules in T-PLL cells which results in a higher content of acid hydrolases. The intriguing relationship of B-PLL with B-CLL is discussed in the light of new data with immunological markers.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Aged
  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols*
  • B-Lymphocytes / immunology
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Drug Therapy, Combination
  • Humans
  • Immunity, Cellular
  • Karyotyping
  • Leukapheresis
  • Leukemia, Experimental / immunology
  • Leukemia, Lymphoid / classification
  • Leukemia, Lymphoid / immunology*
  • Leukemia, Lymphoid / therapy
  • Lymphocyte Activation
  • Mice
  • Middle Aged
  • Phenotype
  • Prednisone / administration & dosage
  • Prognosis
  • Splenectomy
  • T-Lymphocytes / immunology
  • Vincristine / administration & dosage

Substances

  • Antineoplastic Agents
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol